Abstract:
The Korean Association of Urogenital Tract Infection and Inflammation and the Korea Disease Control and Prevention Agency updated the Korean sexually transmitted infections (STIs) guidelines to respond to the changing epidemiologic trends, evolving scientific evidence, and advances in laboratory diagnostics and research. The main recommendations in the Mycoplasma genitalium infection parts of the Korean STIs guidelines 2023 revision are as follows: 1) For initial treatment: azithromycin 500 mg orally in a single dose, then 250 mg once daily for 4 days. 2) In case of treatment failure or recurrence, a macrolide susceptibility/resistance test is required, when susceptibility/resistance test is not feasible, doxycycline or minocycline 100 mg orally twice daily for 7 days, followed by azithromycin 1 g orally on the first day, then azithromycin 500 mg orally once daily for 3 days and then a test-of-cure should be considered 3 weeks after completion of therapy. 3) In case of macrolide sensitivity, doxycycline or minocycline 100 mg orally twice daily for 7 days, followed by azithromycin 1 g orally initial dose, then azithromycin 500 mg orally once daily for 3 days. 4) In case of macrolide resistance, doxycycline or minocycline 100 mg orally twice daily for 7 days, followed by moxifloxacin 400 mg orally once daily for 7 days. In the Korean STIs guideline 2023, macrolide resistance-guided antimicrobial therapy was emphasized due to the increased prevalence of macrolide resistance worldwide. Therefore, in case of treatment failure or recurrence, a macrolide susceptibility/resistance test is required.
摘要:
韩国泌尿生殖道感染和炎症协会和韩国疾病控制和预防机构更新了韩国性传播感染(STIs)指南,以应对不断变化的流行病学趋势,不断发展的科学证据,以及实验室诊断和研究的进展。韩国性传播感染指南2023年修订的生殖支原体感染部分中的主要建议如下:1)对于初始治疗:阿奇霉素500mg单剂量口服,然后每天一次250毫克,持续4天。2)如果治疗失败或复发,需要进行大环内酯敏感性/耐药性试验,当敏感性/抗性测试不可行时,多西环素或米诺环素100毫克,每天两次,持续7天,然后在第一天口服阿奇霉素1克,然后阿奇霉素500mg,每日1次,持续3天,然后在治疗完成后3周应考虑治愈试验.3)在大环内酯敏感性的情况下,多西环素或米诺环素100毫克,每天两次,持续7天,随后是阿奇霉素1克口服初始剂量,然后阿奇霉素500毫克,每天一次,连续3天。4)在大环内酯抗性的情况下,多西环素或米诺环素100毫克,每天两次,持续7天,然后莫西沙星400毫克,每天一次,连续7天。在2023年韩国性传播感染指南中,由于全球大环内酯耐药性的增加,强调了大环内酯耐药性指导的抗菌治疗。因此,如果治疗失败或复发,需要进行大环内酯敏感性/耐药性试验。